
Enric Älvarez MartÃ-nez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4875728/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations. Schizophrenia Research, 2017, 189, 97-103.	1.1	43
2	Letter to the Editor: Deep brain stimulation for schizophrenia. Journal of Neurosurgery, 2016, 125, 229-230.	0.9	8
3	Cognitive functioning after deep brain stimulation in subcallosal cingulate gyrus for treatment-resistant depression: An exploratory study. Psychiatry Research, 2015, 225, 341-346.	1.7	21
4	Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations. Schizophrenia Research, 2015, 161, 261-268.	1.1	106
5	Immediate cerebral metabolic changes induced by discontinuation of deep brain stimulation of subcallosal cingulate gyrus in treatment-resistant depression. Journal of Affective Disorders, 2015, 173, 159-162.	2.0	20
6	The Spanish version of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16): A psychometric analysis in a clinical sample. Journal of Affective Disorders, 2014, 169, 189-196.	2.0	13
7	Microstructural white-matter abnormalities associated with treatment resistance, severity and duration of illness in major depression. Psychological Medicine, 2014, 44, 1171-1182.	2.7	110
8	A psychometric analysis of the Clinically Useful Depression Outcome Scale (CUDOS) in Spanish patients. Journal of Affective Disorders, 2013, 151, 920-923.	2.0	8
9	A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology, 2012, 15, 589-600.	1.0	181
10	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Research, 2012, 200, 693-701.	1.7	29
11	Preclinical and clinical characterization of the selective 5â€HT _{1A} receptor antagonist DUâ€125530 for antidepressant treatment. British Journal of Pharmacology, 2012, 167, 1021-1034.	2.7	40
12	Which Nontraditional Outcomes Should Be Measured in Healthcare Decision-Making in Schizophrenia? A Systematic Review. Perspectives in Psychiatric Care, 2012, 48, 198-207.	0.9	8
13	Regional differences in treatment response and three year course of schizophrenia across the world. Journal of Psychiatric Research, 2012, 46, 856-864.	1.5	16
14	Ventromedial prefrontal spectroscopic abnormalities over the course of depression: A comparison among first episode, remitted recurrent and chronic patients. Journal of Psychiatric Research, 2011, 45, 427-434.	1.5	115
15	A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. Journal of Affective Disorders, 2010, 120, 221-225.	2.0	80
16	Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: Antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients. European Neuropsychopharmacology, 2010, 20, 721-730.	0.3	28
17	Clinical and serotonergic predictors of nonâ€affective acute remitting psychosis in patients with a firstâ€episode psychosis. Acta Psychiatrica Scandinavica, 2009, 119, 71-77.	2.2	10
18	Depressive Relapse After Initial Response to Subcallosal Cingulate Gyrus-Deep Brain Stimulation in a Patient with a Treatment-Resistant Depression: Electroconvulsive Therapy as a Feasible Strategy. Biological Psychiatry, 2009, 66, e11-e12.	0.7	19

ENRIC ÄLVAREZ MARTÄNEZ

#	Article	IF	CITATIONS
19	Remission in schizophrenia: Results from a 1-year follow-up observational study. Schizophrenia Research, 2009, 108, 214-222.	1.1	50
20	Recovery from schizophrenia: Results from a 1-year follow-up observational study of patients in symptomatic remission. Schizophrenia Research, 2009, 115, 58-66.	1.1	75
21	Pindolol augmentation enhances response outcomes in first depressive episodes. European Neuropsychopharmacology, 2009, 19, 516-519.	0.3	24
22	Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug and Alcohol Dependence, 2007, 89, 190-194.	1.6	43
23	Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. Neurolmage, 2006, 29, 662-666.	2.1	38
24	Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical and atypical ant ipsychotics in the treatment of schizophrenia. European Psychiatry, 2006, 21, 11-20.	0.1	52
25	Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatric Genetics, 2006, 16, 25-29.	0.6	51
26	Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 1231-ADAM SPECT study. Psychopharmacology, 2006, 189, 145-153.	1.5	43
27	Dopamine D2 receptor occupancy by risperidone: Implications for the timing and magnitude of clinical response. Psychiatry Research - Neuroimaging, 2006, 148, 175-183.	0.9	19
28	Injectable Atypical Antipsychotics for Agitation in Borderline Personality Disorder. Pharmacopsychiatry, 2006, 39, 117-118.	1.7	31
29	Is grey literature essential for a better control of publication bias in psychiatry? An example from three meta-analyses of schizophrenia. European Psychiatry, 2005, 20, 550-553.	0.1	46
30	Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 91-96.	2.5	19
31	Regulation of Platelet α2A-Adrenoceptors, Gi Proteins and Receptor Kinases in Major Depression: Effects of Mirtazapine Treatment. Neuropsychopharmacology, 2004, 29, 580-588.	2.8	44
32	Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 767-770.	2.5	12
33	SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients. A pilot study. Psychiatry Research - Neuroimaging, 2001, 106, 151-160.	0.9	70
34	Augmentation of Fluoxetine's Antidepressant Action by Pindolol: Analysis of Clinical, Pharmacokinetic, and Methodologic Factors. Journal of Clinical Psychopharmacology, 2001, 21, 36-45.	0.7	60
35	Relationship Between Blood Serotonergic Variables, Melancholic Traits, and Response to Antidepressant Treatments. Journal of Clinical Psychopharmacology, 1998, 18, 222-230.	0.7	31
36	Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet, The, 1997, 349, 1594-1597.	6.3	304

#	Article	IF	CITATIONS
37	Predicting outcome of lithium added to antidepressants in resistant depression. Journal of Affective Disorders, 1997, 42, 179-186.	2.0	30
38	Effects of the antidepressant drug tianeptine on plasma and platelet serotonin of depressive patients and healthy controls. Journal of Affective Disorders, 1993, 29, 227-234.	2.0	28
39	Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. Journal of Affective Disorders, 1992, 25, 243-249.	2.0	69
40	Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. Psychopharmacology, 1989, 99, 328-332.	1.5	43
41	Urinary phenylacetic acid excretion in depressive patients. Acta Psychiatrica Scandinavica, 1988, 78, 208-210.	2.2	21
42	Enhanced binding of [³ H] (â€) adrenaline to platelets of depressed patients with melancholia: Effect of longâ€ŧerm clomipramine treatment. Acta Psychiatrica Scandinavica, 1987, 75, 150-157.	2.2	46
43	Decreased plasma serotonin in melancholic patients: A study with clomipramine. Biological Psychiatry, 1987, 22, 1429-1438.	0.7	81